Influence of Mixed Chimerism on Outcome in Children With Anaemia After Haematopoietic Stem Cell Transplantation

Overview

Journal In Vivo

Specialty Oncology

Date 2019 Oct 31

PMID 31662537

Citations 1

Authors

Monika Lejman

Joanna Zawitkowska

Agnieszka Zaucha-Prazmo

Magdalena Cienkusz

Aleksandra Mroczkowska

Jerzy Kowalczyk

Katarzyna Drabko

Affiliations

Soon will be listed here.

Abstract

Background/aim: In patients with non-malignant diseases, mixed chimerism is not a rare phenomenon. The clinical impacts of chimerism following allogeneic haematopoietic stem cell transplantation (allo-HSCT) in children with congenital anaemia (CA) and severe aplastic anaemia (SAA) were analysed.

Patients And Methods: We studied twenty-seven consecutive children with congenital and acquired anaemia who had undergone allogeneic haematopoietic stem cell transplantations. In the observed group of patients, the median of the follow-up was 6.12 years (2.00-14.8 years).

Results: Overall survival (OS) did not depend on the type of disease p=0.1. OS did not significantly differ in patients who received more than 5x10/kg stem cells (91%) and those who received less than 5x10/kg (85%) (p=0.61). Two patterns of stable mixed chimerism (SMC) were observed: SMC (95-97% cells of the donor), and SMC with a fluctuation between 50-90% of the cells of the donor. None of the surviving patients received immunosuppression treatments of chronic Graft-versus-Host Disease (cGvHD).

Conclusion: Our results showed that mixed chimerism did not influence the survival of children with congenital and aplastic anaemia following allo-HSCT.

Citing Articles

Acute Lymphoblastic Leukemia in Children: Better Transplant Outcomes After Total Body Irradiation-based Conditioning.

Styczynski J, Debski R, Czyzewski K, Gagola K, Marquardt E, Roszkowski K In Vivo. 2021; 35(6):3315-3320.

PMID: 34697163 PMC: 8627707. DOI: 10.21873/invivo.12627.

References

Bonfim C, Ribeiro L, Nichele S, Bitencourt M, Loth G, Koliski A . Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia. Biol Blood Marrow Transplant. 2016; 22(7):1257-1263. DOI: 10.1016/j.bbmt.2016.03.007. View

Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S . Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia. 1999; 13(12):2059, 2060-9. View

Miano M, Dufour C . The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015; 101(6):527-35. DOI: 10.1007/s12185-015-1787-z. View

Stikvoort A, Gertow J, Sundin M, Remberger M, Mattsson J, Uhlin M . Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients. Biol Blood Marrow Transplant. 2013; 19(5):838-44. DOI: 10.1016/j.bbmt.2013.02.015. View

Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K . First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014; 99(12):1784-91. PMC: 4258757. DOI: 10.3324/haematol.2014.109355. View

Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T . How and when should we monitor chimerism after allogeneic stem cell transplantation?. Bone Marrow Transplant. 2004; 35(2):107-19. DOI: 10.1038/sj.bmt.1704715. View

Iwafuchi H . The histopathology of bone marrow failure in children. J Clin Exp Hematop. 2018; 58(2):68-86. PMC: 6413145. DOI: 10.3960/jslrt.18018. View

Haines H, Bleesing J, Davies S, Hornung L, Jordan M, Marsh R . Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2014; 21(2):288-92. DOI: 10.1016/j.bbmt.2014.10.010. View

Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M . Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. PLoS One. 2016; 11(5):e0154737. PMC: 4859543. DOI: 10.1371/journal.pone.0154737. View

10.

Park M, Koh K, Seo J, Im H . Clinical implications of chimerism after allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases. Korean J Hematol. 2012; 46(4):258-64. PMC: 3259518. DOI: 10.5045/kjh.2011.46.4.258. View

11.

Madden L, Hayashi R, Chan K, Pulsipher M, Douglas D, Hale G . Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016; 22(8):1467-1472. DOI: 10.1016/j.bbmt.2016.04.025. View

12.

Hassan R, Bonamino M, Braggio E, Lobo A, Seuanez H, Tabak D . A systematic approach to molecular quantitative determination of mixed chimaerism following allogeneic bone marrow transplantation: an analysis of its applicability in a group of patients with severe aplastic anaemia. Eur J Haematol. 2004; 73(3):156-61. DOI: 10.1111/j.1600-0609.2004.00296.x. View

13.

Svenberg P, Mattsson J, Ringden O, Uzunel M . Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism. Bone Marrow Transplant. 2009; 44(11):757-63. DOI: 10.1038/bmt.2009.82. View

14.

Faraci M, Bagnasco F, Leoni M, Giardino S, Terranova P, Subissi L . Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases. Biol Blood Marrow Transplant. 2018; 24(5):1088-1093. DOI: 10.1016/j.bbmt.2017.12.801. View

15.

Tripathi P, Tripathi A, Kumar A, Ahmad R, Balapure A, Vishwakerma A . DNA aneuploidy study for early detection of chromosomal abnormality in patients with aplastic anemia: prognostic and therapeutic implications. In Vivo. 2009; 22(6):837-44. View

16.

Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A . Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11-8. DOI: 10.3324/haematol.10075. View

17.

Marsh J . Treatment of acquired aplastic anemia. Haematologica. 2007; 92(1):2-5. DOI: 10.3324/haematol.11107. View

18.

Hoelle W, Beck J, Dueckers G, Kreyenberg H, Lang P, Gruhn B . Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia. Bone Marrow Transplant. 2003; 33(2):219-23. DOI: 10.1038/sj.bmt.1704337. View

19.

Clark J, Scott S, Jack A, Lee H, Mason J, Carter G . Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment.... Br J Haematol. 2014; 168(1):26-37. DOI: 10.1111/bjh.13073. View

20.

Lawler M, McCann S, Marsh J, Ljungman P, Hows J, Vandenberghe E . Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine.... Br J Haematol. 2009; 144(6):933-45. DOI: 10.1111/j.1365-2141.2008.07533.x. View